Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
LB-102 by LB Pharmaceuticals for Schizophrenia: Likelihood of Approval
LB-102 is under clinical development by LB Pharmaceuticals and currently in Phase II for Schizophrenia. According to GlobalData, Phase II...